Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TCDA | Common Stock | Sale | -$228K | -1.03M | -10.06% | $0.22* | 9.25M | Nov 22, 2022 | See Footnotes | F1, F2, F3 |
transaction | TCDA | Common Stock | Sale | -$1.18M | -5.62M | -60.75% | $0.21* | 3.63M | Nov 23, 2022 | See Footnotes | F2, F3 |
transaction | TCDA | Common Stock | Sale | -$798K | -3.63M | -100% | $0.22* | 0 | Nov 25, 2022 | See Footnotes | F2, F3 |
Id | Content |
---|---|
F1 | Represents the weighted average sale price of the shares of the Issuer's common stock ("Shares") sold, ranging from a low of $0.21 to a high of $0.22 per Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares sold at each separate price. |
F2 | The Shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. |
F3 | This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |